Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

BCDA

BioCardia Inc.

Oct 04 • 04:00PM ET

2.74

Dollar change -0.07
Percentage change -2.49	%

Healthcare • Biotechnology • USA • NASD

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.33	Insider Own	32.62%	Shs Outstand	3.50M	Perf Week	-6.80%
Market Cap	9.59M	Forward P/E	6.52	EPS next Y	0.42	Insider Trans	0.46%	Shs Float	2.28M	Perf Month	9.60%
Income	-8.56M	PEG	-	EPS next Q	-1.19	Inst Own	2.47%	Short Float	6.63%	Perf Quarter	-5.84%
Sales	0.43M	P/S	22.30	EPS this Y	38.67%	Inst Trans	-31.28%	Short Ratio	0.18	Perf Half Y	-52.62%
Book/sh	-0.92	P/B	-	EPS next Y	108.30%	ROA	-184.48%	Short Interest	0.15M	Perf Year	-54.30%
Cash/sh	0.41	P/C	6.75	EPS next 5Y	-	ROE	-703.62%	52W Range	1.96 - 23.25	Perf YTD	-72.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	30.13%	ROI	-	52W High	-88.22%	Beta	1.25
Dividend TTM	-	Quick Ratio	0.39	Sales past 5Y	100.50%	Gross Margin	1.64%	52W Low	40.07%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	0.39	EPS Y/Y TTM	47.60%	Oper. Margin	-2010.75%	RSI (14)	48.82	Volatility	8.97% 10.89%
Employees	20	Debt/Eq	-	Sales Y/Y TTM	0.71%	Profit Margin	-1999.77%	Recom	1.00	Target Price	25.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	65.20%	Payout	-	Rel Volume	0.05	Prev Close	2.81
Sales Surprise	-94.00%	EPS Surprise	-780.00%	Sales Q/Q	-93.02%	Earnings	Aug 13 AMC	Avg Volume	834.33K	Price	2.74
SMA20	0.00%	SMA50	-3.10%	SMA200	-47.00%	Trades		Volume	42,684	Change	-2.49%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

Sep-18-24 08:30AM	BioCardia Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.39%
Sep-09-24 04:05PM	BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +6.17% +6.64%
Aug-30-24 08:00AM	BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.13%
Aug-29-24 08:30AM	BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family (GlobeNewswire) +82.73%
Aug-21-24 07:00AM	FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment (GlobeNewswire) -12.91%
04:30PM	Loading…
Aug-13-24 04:30PM	BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-07-24 07:00AM	BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024 (GlobeNewswire) +5.95%
Jul-30-24 07:00AM	BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Jul-25-24 07:00AM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure (GlobeNewswire)
Jul-17-24 07:00AM	BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application (GlobeNewswire)
Jul-08-24 07:00AM	CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction (GlobeNewswire)
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -7.80%
Jun-07-24 07:00AM	BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach (GlobeNewswire) -14.78%
Jun-04-24 07:52AM	BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace)
May-21-24 05:00PM	BioCardia Announces Reverse Stock Split (GlobeNewswire) -23.82%
03:08AM	Loading…
May-15-24 03:08AM	BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ... (GuruFocus.com)
May-14-24 08:56PM	BCDA Stock Earnings: BioCardia Reported Results for Q1 2024 (InvestorPlace)
04:02PM	BioCardia Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
May-09-24 07:00AM	BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024 (GlobeNewswire)
May-01-24 07:00AM	BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes (GlobeNewswire)
Apr-25-24 09:00AM	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort (GlobeNewswire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Apr-01-24 02:30PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 05:58AM	Q4 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 08:53PM	BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:00PM	BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results (GlobeNewswire)
Mar-20-24 07:00AM	BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 (GlobeNewswire)
Mar-13-24 07:00AM	BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership (GlobeNewswire)
Mar-12-24 07:00AM	BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study (GlobeNewswire) -9.49%
Mar-04-24 09:27AM	BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy (FierceBiotech.com) -21.51%
08:00AM	Loading…
08:00AM	BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure (GlobeNewswire)
Feb-08-24 07:00AM	BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA (GlobeNewswire) -10.34%
Jan-31-24 07:00AM	BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -5.66%
Jan-03-24 07:00AM	BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders (GlobeNewswire)
Dec-19-23 07:00AM	BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Dec-18-23 07:16AM	BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes (GlobeNewswire) +8.32%
Nov-29-23 07:00AM	BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval (GlobeNewswire)
Nov-16-23 12:56PM	BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27%
Nov-15-23 11:04AM	BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks) -11.68%
Nov-14-23 07:15AM	BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +168.17%
Nov-09-23 12:48PM	BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.75%
06:59AM	Q3 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 05:52PM	BioCardia Inc (BCDA) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com) +6.10%
05:50PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Nov-01-23 05:04PM	BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023 (GlobeNewswire)
Oct-12-23 11:08AM	BioCardia (BCDA) Up on Plans for Second Heart Failure Study (Zacks) -13.88%
Oct-11-23 06:00AM	BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II (GlobeNewswire) +28.30%
Sep-06-23 10:31AM	BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study (Zacks) -12.59%
07:15AM	BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs (GlobeNewswire)
Sep-05-23 07:15AM	BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial (GlobeNewswire) -25.54%
Aug-11-23 09:29AM	BioCardia, Inc. (NASDAQ:BCDA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-09-23 06:05PM	BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.28%
04:05PM	BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Aug-02-23 07:00AM	BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023 (GlobeNewswire)
Jul-24-23 07:00AM	BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected (GlobeNewswire) -44.70%
Jul-10-23 08:11AM	Those who invested in BioCardia (NASDAQ:BCDA) a year ago are up 86% (Simply Wall St.)
Jul-05-23 07:00AM	BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japans Pharmaceutical Medical Device Agency (GlobeNewswire)
Jun-20-23 05:14PM	BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study (GlobeNewswire) +6.41% +12.45%
Jun-08-23 07:00AM	BioCardia Announces Helix Biotherapeutic Delivery Patent Issuance in Japan (GlobeNewswire) +6.53%
May-28-23 08:08AM	Joseph Daly Spends US$177k Buying BioCardia Shares \ (Simply Wall St.)
May-23-23 07:00AM	BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study (GlobeNewswire)
May-12-23 06:06AM	BioCardia First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-10-23 05:45PM	BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	BioCardia Reports First Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
May-09-23 07:00AM	BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications (GlobeNewswire)
May-03-23 08:00PM	BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023 (GlobeNewswire)
Apr-28-23 07:00AM	BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available (GlobeNewswire)
Apr-04-23 07:00AM	BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies (GlobeNewswire)
Apr-01-23 12:47PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:05AM	We're Keeping An Eye On BioCardia's (NASDAQ:BCDA) Cash Burn Rate (Simply Wall St.)
Mar-29-23 08:15AM	BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results (GlobeNewswire)
Mar-16-23 07:00AM	BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023 (GlobeNewswire)
Mar-06-23 01:06PM	BioCardia Outlines Detailed Cell Therapy Data From Heart Failure Study (Benzinga)
07:00AM	Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting (GlobeNewswire)
Feb-01-23 06:30AM	BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients (GlobeNewswire) -7.48%
Jan-31-23 05:39AM	Shareholders in BioCardia (NASDAQ:BCDA) are in the red if they invested five years ago (Simply Wall St.)
Dec-22-22 07:00AM	BioCardia Letter to Shareholders (GlobeNewswire)
Dec-21-22 05:07AM	Insider Buying: The BioCardia, Inc. (NASDAQ:BCDA) Independent Director Just Bought 14% More Shares (Simply Wall St.) +6.55%
Dec-15-22 07:00AM	BioCardia Announces $3.6 Million Private Placement of Common Stock (GlobeNewswire)
Dec-06-22 07:00AM	BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure (Business Wire)
Nov-09-22 05:35PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results (GlobeNewswire)
12:00PM	BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-02-22 05:31PM	BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022 (GlobeNewswire)
Oct-03-22 01:33PM	BioCardia's Heart Failure Cell Therapy Shows 100% Survival At Two Years (Benzinga) +5.67%
07:00AM	BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting (GlobeNewswire)
Sep-14-22 07:00AM	CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting (GlobeNewswire)
Sep-09-22 07:00AM	BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE) (GlobeNewswire)
Sep-08-22 07:00AM	BioCardia to Participate in Cantor Fitzgeralds Cell and Genetic Medicines Conference (GlobeNewswire)
Sep-06-22 11:03AM	Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation (Simply Wall St.) -5.26%
Aug-31-22 07:00AM	BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial (GlobeNewswire)
Aug-24-22 09:40AM	Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year? (Zacks)
07:00AM	BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRocks Cell Therapy to Treat Heart Failure (GlobeNewswire)
Aug-10-22 05:15PM	BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.34%
04:30PM	Edited Transcript of BCDA.OQ earnings conference call or presentation 10-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results (GlobeNewswire)
Aug-04-22 02:04PM	BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022 (GlobeNewswire) +5.88%
Aug-01-22 08:00AM	BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial (GlobeNewswire)
Jul-12-22 08:15AM	BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia (GlobeNewswire)

BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Altman Peter	President and CEO	Jul 01 '24	Buy	3.05	300	915	39,745	Jul 02 04:12 PM
Altman Peter	President and CEO	Jun 28 '24	Buy	2.99	200	598	39,445	Jul 02 04:12 PM
Altman Peter	President and CEO	Jun 21 '24	Buy	3.29	500	1,645	39,245	Jun 24 08:46 AM
Altman Peter	President and CEO	Jun 14 '24	Buy	3.52	500	1,760	38,745	Jun 17 07:00 AM
Altman Peter	President and CEO	Jun 10 '24	Buy	3.36	1,000	3,360	38,245	Jun 12 07:00 AM
Altman Peter	President and CEO	Apr 19 '24	Buy	0.37	2,750	1,013	558,697	Apr 19 05:38 PM
Altman Peter	President and CEO	Mar 28 '24	Buy	0.39	500	195	555,947	Mar 28 07:33 PM
Altman Peter	President and CEO	Feb 13 '24	Buy	0.46	108,108	50,000	555,447	Feb 15 07:00 AM
FROST PHILLIP MD ET AL	10% Owner	Jan 19 '24	Sale	0.43	129,802	55,815	1,896,025	Jan 22 08:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCDA

BioCardia Inc.

Upgrade your FINVIZ experience